EGFR and non-small cell lung carcinoma: In total, 48.6% (17/35) of the NSCLC patients showed positive PD‐L1 expression in TCs of EGFR Ex20ins tumors; this percentage was markedly higher than that in HER2‐mutant patients (48.6% vs. 19.0%, P = 0.027), whereas the distribution of CD4+ or CD8+ TILs was similar in these two groups (P = 0.672, P = 0.888, Table 1).